Skip to Content
Merck
CN
  • Age-associated mitochondrial DNA mutations cause metabolic remodelling that contributes to accelerated intestinal tumorigenesis.

Age-associated mitochondrial DNA mutations cause metabolic remodelling that contributes to accelerated intestinal tumorigenesis.

Nature cancer (2020-10-20)
Anna Lm Smith, Julia C Whitehall, Carla Bradshaw, David Gay, Fiona Robertson, Alasdair P Blain, Gavin Hudson, Angela Pyle, David Houghton, Matthew Hunt, James N Sampson, Craig Stamp, Grace Mallett, Shoba Amarnath, Jack Leslie, Fiona Oakley, Laura Wilson, Angela Baker, Oliver M Russell, Riem Johnson, Claire A Richardson, Bhavana Gupta, Iain McCallum, Stuart Ac McDonald, Seamus Kelly, John C Mathers, Rakesh Heer, Robert W Taylor, Neil D Perkins, Doug M Turnbull, Owen J Sansom, Laura C Greaves
ABSTRACT

Oxidative phosphorylation (OXPHOS) defects caused by somatic mitochondrial DNA (mtDNA) mutations increase with age in human colorectal epithelium and are prevalent in colorectal tumours, but whether they actively contribute to tumorigenesis remains unknown. Here we demonstrate that mtDNA mutations causing OXPHOS defects are enriched during the human adenoma/carcinoma sequence, suggesting they may confer a metabolic advantage. To test this we deleted the tumour suppressor Apc in OXPHOS deficient intestinal stem cells in mice. The resulting tumours were larger than in control mice due to accelerated cell proliferation and reduced apoptosis. We show that both normal crypts and tumours undergo metabolic remodelling in response to OXPHOS deficiency by upregulating the de novo serine synthesis pathway (SSP). Moreover, normal human colonic crypts upregulate the SSP in response to OXPHOS deficiency prior to tumorigenesis. Our data show that age-associated OXPHOS deficiency causes metabolic remodelling that can functionally contribute to accelerated intestinal cancer development.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5-Iodo-2′-deoxyuridine, ≥99% (HPLC)
Sigma-Aldrich
5-Chloro-2′-deoxyuridine, thymidine analog
Roche
In Situ Cell Death Detection Kit, POD, sufficient for ≤50 tests